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Objective. Type 2 diabetes mellitus (T2DM) is known to be associated with increased cardiovascular risk. The aim of this study was
therefore to investigate the independent effects of hyperglycaemia, hypoglycaemia, and glucose variability on microvascular and
macrovascular disease in T2DM. Methods. Subjects with T2DM of <10 years duration and on stable antiglycaemic treatment
underwent carotid intima-media thickness (CIMT), ankle-brachial index (ABI), albumin-creatinine ratio (ACR), and HbA1c
measurement, as well as 72-hour continuous glucose monitoring. Macrovascular disease was defined as one or more of the
following: history of ischaemic heart disease (IHD), cerebrovascular accident (CVA), ABI< 0.9, or abnormal CIMT. Results. The
study population comprised 121 subjects with T2DM (89 males : 32 females). The mean age was 62.6 years, and the mean DM
duration was 3.7 years. Macrovascular disease was present in 71 patients (58.7%). In multivariate logistic regression analysis, body
surface area (BSA) (OR 18.88 (95% CI 2.20–156.69), p = 0 006) and duration of blood glucose (BG)< 3.9mmol/L (OR 1.12 (95%
CI 1.014–1.228), p = 0 024) were independent predictors of macrovascular disease. BSA (OR 12.6 (95% CI 1.70–93.54), p = 0 013)
and duration of BG< 3.9mmol/L (OR 1.09 (95% CI 1.003–1.187), p = 0 041) were independent predictors of abnormal CIMT.
Area under the curve for BG> 7.8mmol/L (β= 15.83, p = 0 005) was the sole independent predictor of albuminuria in generalised
linear regression. Conclusions. This study demonstrates that hypoglycaemia is associated with the occurrence of atherosclerotic
disease while hyperglycaemia is associated with microvascular disease in a Caucasian population with T2DM of recent duration.
1. Introduction
Diabetes is known to be associated with both microvascular
and macrovascular disease [1]. Whilst good glycaemic con-
trol has been consistently shown to reduce microvascular dis-
ease, most intervention studies have failed to document a
reduction in macrovascular disease outcomes [2, 3].
One possible explanation for this discrepancy is the det-
rimental effect of hypoglycaemia. Östgren and colleagues
have recently reported a U-shaped relationship of HbA1c
with cardiovascular events, including mortality [4]. A recent
meta-analysis has also confirmed that hypoglycaemia is
associated with a twofold increased risk of cardiovascular dis-
ease in type 2 diabetes [5]. Furthermore, both hyperglycae-
mia and hypoglycaemia following acute coronary syndrome
have been associated with increased mortality [6, 7] The tra-
ditional explanations of these observations are the proar-
rhythmogenic effect of hypoglycaemia as a consequence of
catecholamine release and QTc prolongation [8, 9] and the
unavailability of an energy substrate to the myocardium dur-
ing hypoglycaemia leading to an ischaemia equivalent [10].
However, the increased mortality extends beyond the hypo-
glycaemic episode itself. Although a hypoglycaemic episode
is known to predict future ones [11], this is unlikely to be
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the sole mechanism. Another possible contributory mecha-
nism that has not been well investigated is the possibility that
hypoglycaemia may accelerate atherosclerosis, as suggested
by some animal studies. For example, Yasunari and colleagues
reported that repeated hypoglycaemia worsens injury-
provoked intimal thickening in a male Goto-Kakizaki rat
carotid artery [12], whilst Jin and colleagues reported that
hypoglycaemia inducedmonocyte adhesion to rat aortic endo-
thelium [13]. Furthermore, a small study found higher carotid
and femoral intima-media thickness in 25 subjects with type 1
diabetes and with repeated hypoglycaemic episodes when
compared to20subjectswith type1diabetesbutwithouthypo-
glycaemia [14]. However, continuous glucosemonitoring was
not performed, and therefore, hyperglycaemic episodes were
not captured. Since the two groups had similar HbA1c, it is
likely that the hypoglycaemic group also had more hyper-
glycaemia, which might conceivably have contributed to
increased intima-media thickness.
Another possible explanation of the failure of clinical tri-
als to demonstrate a beneficial effect of glycaemic control is
that none of them targeted reducing fluctuations in blood
glucose. Indeed, many forms of treatment may increase
blood glucose fluctuations. Acute fluctuations in blood glu-
cose have been shown to be associated with increased mortal-
ity [15]. This may be mediated by endothelial dysfunction,
oxidative stress, and endothelial cell apoptosis [16]. Such
effects of glucose fluctuations could predispose to both
microvascular and macrovascular disease.
The aim of this study was therefore to investigate the
independent effects of hyperglycaemia, hypoglycaemia,
and glucose variability on microvascular and macrovascu-
lar disease in type 2 diabetes. Urinary albumin-creatinine
served as a marker of microvascular disease. Ankle-brachial
index, carotid intima-media thickness, and documented car-
diovascular disease served as markers of macrovascular
disease. 72-hour continuous glucose monitoring was used
to assess hypoglycaemia, hyperglycaemia, and glucose var-
iability. HBA1c and fructosamine served as additional gly-
caemic indexes.
2. Methods
The study was cross-sectional in nature; data collection was
performed over a one-year period, from April 2015 to April
2016. Patients were randomly selected from the list of outpa-
tients attending the Diabetes Centre, Mater Dei Hospital,
Malta, during the year 2014. The inclusion criteria were sub-
jects who were diagnosed with type 2 DM according to
World Health Organization criteria within the last ten years
and were on stable antiglycaemic treatment. Patients suffer-
ing from dementia or mental illnesses with the consequent
inability to give an informed consent with regard to partici-
pation in the study were excluded from the study. Other
exclusion criteria included recent admission to hospital with
a diabetes-related complication such as hyperglycaemic
hyperosmolar ketoacidosis, liver failure, or kidney failure,
as well as any other factors that result in glycaemic fluctua-
tions. The study protocol was approved by the University
of Malta Research Ethics Committee. All participants gave
written informed consent.
2.1. Clinical and Laboratory Measurements. The presence of
history of ischaemic heart disease and of cerebrovascular dis-
ease was ascertained by use of a questionnaire and by review
of medical notes. Height and weight were measured using a
calibrated balance and a stadiometer, with the subjects wear-
ing light clothing and without shoes. Body mass index (BMI)
was calculated as weight divided by height squared. Waist
circumference was measured to the nearest 0.5 cm in the hor-
izontal plane at the midpoint between the lowest rib and the
iliac crest [17]. The waist index was calculated as waist cir-
cumference (cm) divided by 94 for men and 80 for women
[18] Office blood pressure was measured in the supine posi-
tion after 5min of rest.
All subjects underwent routine blood investigations in
the fasting state on the day of the clinical examination.
No medication was taken on the morning of the examina-
tion. Patients who were treated with insulin discontinued
injections after 22:00 on the day preceding the examina-
tion. Estimated glomerular filtration rate (eGFR) was calcu-
lated using the Modified Diet in Renal Disease (MDRD)
formula (National Kidney Foundation Calculator for Health-
care Professionals). Haemoglobin A1c (measured using high-
performance liquid chromatography) and fructosamine were
taken as markers of glycaemic control. Urine albumin was
measured by an immunoturbidometric technique (Roche
Diagnostics, Mannheim, Germany). Creatinine was mea-
sured by a kinetic colorimetric test using the Jaffe reaction
(Roche Diagnostics). Albumin-creatinine ratio (ACR) was
assessed in all patients as a marker of microvascular disease.
Body surface area was provided by the Esaote machine used
to perform CIMT by inputting weight and height.
2.2. Continuous Glucose Monitoring. Seventy-two-hour sub-
cutaneous continuous glucose monitoring (CGM) was per-
formed in all study participants on an ambulatory basis
using the iPro2 continuous glucose-monitoring system
(Medtronic MiniMed, Northridge, CA, USA). Participants
were advised to pursue their normal daily living without
alterations in their usual diet, exercise, and medications
taken. Data from the iPro2 were uploaded online via the
CareLink iPro software. The following parameters were
extracted for each patient: mean blood glucose (MBG),
standard deviation of blood glucose (SD), the highest
and lowest blood glucose values, the number of high and
low excursions, the area under the curve when the blood
glucose was higher than 7.8mmol/L (AUC> 7.8), the area
under the curve when the blood glucose was lower than
3.9mmol/L (AUC< 3.9), the duration (%) when the blood
glucose was higher than 7.8mmol/L, the duration (%)
when the blood glucose was lower than 3.9mmol/L, and
the duration (%) when the blood glucose was between
3.9mmol/L and 7.8mmol/L.
2.3. Carotid Intima-Media Thickness Measurement. Carotid
intima-media thickness (CIMT) was assessed in both com-
mon carotid arteries in each participant using the Esaote
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Quality intima media thickness (QIMT®). The common
carotid artery was utilised since, according to the Mannheim
consensus, it increases the accuracy and reproducibility of
the measurements obtained. The Esaote QIMT utilises a
radio frequency signal to enable measurement of the CIMT
with high spatial resolution. The QIMT tool automatically
provides accurate measurements of all the parameters which
are independent from both the investigator and device set-
tings. Results were categorised as normal or abnormal using
age-specific cut-offs, which have been validated in large
worldwide databases [19]. Furthermore, all study partici-
pants were screened for the presence of carotid plaques in
view that the combination of plaque area and thickness have
greater value in predicting CVD compared to the thickness
alone [17]. Patients with an increased CIMT as assessed by
QIMT and/or presence of carotid plaque were categorised
as having an abnormal CIMT.
2.4. Clinical Definitions. eGFR was defined as being low if
it was <60mL/min/1.73m2. PAD was defined as an ABI
of ≤0.9. The mean arterial pressure was the average arterial
pressure during a single cardiac cycle and pulse pressure
the difference between the systolic and diastolic blood pres-
sure readings. Macrovascular disease was defined as the pres-
ence of one or more of the following: history of ischaemic
heart disease (IHD) or cerebrovascular accident (CVA),
ABI< 0.9, or abnormal CIMT.
2.5. Statistical Analysis.All data were analysed using SPSS ver-
sion 24.0 for Windows. Results are presented as mean± stan-
dard deviation (SD) or median (interquartile range (IQR)).
Continuous variables were checked for normality of distri-
bution using the Kolmogorov-Smirnov method. Compari-
sons of continuous variables between two groups were made
using independent sample t-test for normally distributed var-
iables. Fornonparametric variables, theMann–WhitneyU test
was used for comparison of 2 groups. Categorical variables
were compared using the χ2 test. The Pearson test was used
to test correlation of normally distributed variables, and the
Spearman test was used for comparison of non-normally dis-
tributed variables.
Univariate followed by multivariate analyses (logistic
regression analyses) were performed to identify independent
determinants of both the occurrence of macrovascular
disease and abnormal CIMT in the study population.
Variables were entered into the regression model if their
p value was <0.1 in univariate analysis. Predictors were
removed from the model if their p value exceeded 0.05.
With regard to ACR, univariate followed by multi-
variate analysis was again performed with variables with a
p value< 0.1 in univariate analysis being included in the mul-
tivariate model; however, a generalised linear model was per-
formed as multivariate analysis in view that ACR exhibited a
gamma distribution (a right-skewed distribution). All tests
were two-sided, and a p value of <0.05 was considered to be
statistically significant.
Sample size was determined so as to have statistical
power of 90% to detect a moderate effect size (f 2 = 0 15)
at α = 0 05.
2.6. Role of Funding Source. The study sponsor had no role in
study design; in the collection, analysis, and interpretation of
data; in the writing of the report; and in the decision to sub-
mit the paper for publication. The authors had full access to
the data.
3. Results
3.1. Characteristics of Study Population. The study popula-
tion comprised 121 T2DM subjects of Caucasian origin.
The baseline characteristics are outlined in Table 1, whilst
continuous glucose-monitoring data are shown in Table 2.
Patients had reasonably well-controlled diabetes with a
median HbA1c of 6.8% (45mmol/mol), a median fasting
plasma glucose of 7.08mmol/L, and a mean blood glucose
(MBG) during CGM of 7.9mmol/L. Hyperglycaemic epi-
sodes were more prevalent than hypoglycaemic episodes as
shown by the number of high and low excursions, the
AUC> 7.8mmol/L and AUC< 3.9mmol/L, as well as dura-
tion of BG> 7.8mmol/L, between 3.9 and 7.8mmol/L,
and < 3.9mmol/L. However, none of the study participants
reported hypoglycaemic episodes, indicating that all these
episodes were subclinical. There were no patients with
missing data.
3.2. Predictors of Macrovascular Disease. Seventy-two sub-
jects exhibited macrovascular disease. Univariate followed
by multivariate analysis was performed to identify predictors
of macrovascular disease in the study population. The results
of univariate analysis are shown in Tables 3–5. In univariate
analysis, the following variables had a p value< 0.1 and were
thus included in the multivariate model: body surface
area (BSA), smoking pack years, HDL cholesterol, triglyc-
erides, ESR, lowest blood glucose (BG) value, AUC for
BG< 3.9mmol/L, and duration of BG< 3.9mmol/L. Inmulti-
variate logistic regression analysis, BSA (OR 18.88 (95% CI
2.20–156.69), p = 0 006) and duration of BG< 3.9mmol/L
(OR 1.12 (95% CI 1.014–1.228), p = 0 024) were shown to be
independent predictors ofmacrovascular disease. The relation
between presence of cardiovascular disease and duration of
BG< 3.9mmol/L is shown in Figure 1.
3.3. Predictors of Abnormal Carotid Intima-Media Thickness.
In the study population, 64 subjects had abnormal CIMT
(composite of increased CIMT and presence of carotid
plaque). In univariate analysis, the following variables had a
p value< 0.1: age, DM duration, smoking pack years, BSA,
white cell count, eGFR, ESR, and duration of BG<3.9mmol/L.
These variables were consequently included in the multi-
variate model.
Binary logistic regression analysis revealed that BSA
(OR 12.6 (95% CI 1.70–93.54), p = 0 013) and duration
of BGM< 3.9mmol/L (OR 1.09 (95% CI 1.003–1.187),
p = 0 041) were independent predictors of abnormal CIMT.
The relation between abnormal CIMT and duration of
BG< 3.9mmol/L is shown in Figure 1.
3.4. Predictors of Albuminuria.The following had p value< 0.1
in univariate analysis: low eGFR (<60mL/min/1.73m2),
white cell count, HDL cholesterol, triglycerides, uric acid,
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BMI, WI, MBG, SD, AUC for BG> 7.8mmol/L, duration
of BG> 7.8mmol/L, duration of BG between 3.9 and
7.8mmol/L, and highest BG value recorded. Generalised
linear regression model revealed AUC for BG> 7.8mmol/L
(β = 15 83, p = 0 005) to be the sole independent predictor
of albuminuria.
4. Discussion
The present study found that the duration of blood glu-
cose< 3.9mmol/L was significantly and independently asso-
ciated with abnormal CIMT and with the composite of
abnormal CIMT, ABI, coronary artery disease, and cerebro-
vascular disease in subjects with type 2 diabetes. This sug-
gests that hypoglycaemia may predispose to atherosclerosis.
Table 1: Baseline demographic and clinical findings of study
population.
Patient characteristics (n = 121) Values
Age (years)† 64 (57–68)
Male : female (n (%)) 89 (73.6) : 32 (26.4)
Diabetes duration (years)† 3 (2–5)
Smoking (current/ex/
nonsmokers) (n (%))
22 (18.2)/41 (33.9)/58 (47.9)
Hypertension (n (%)) 80 (66.1)
Hyperlipidaemia (n (%)) 87 (71.9)
Ischaemic heart disease (n (%)) 15 (12.4)
Peripheral arterial disease (n (%)) 7 (5.8)
Cerebrovascular accident/transient
ischaemic attack (n (%))
3 (2.5)
Abnormal carotid intima-media
thickness (n (%))
64 (52.9)
Macrovascular disease (n (%)) 72 (59.5)
Chronic kidney disease (n (%)) 9 (7.4)
On metformin (n (%)) 109 (90.1)
On sulphonylurea (n (%)) 36 (29.8)
On gliptins (n (%)) 6 (5)
On insulin (n (%)) 6 (5)
On angiotensin-converting enzyme
inhibitor/on angiotensin receptor
blocker (n (%))
77 (63.6)
On β-blocker (n (%)) 22 (18.2)
On calcium channel blocker (n (%)) 23 (19)
On diuretic (n (%)) 33 (23.7)
On aspirin (n (%)) 38 (31.4)
On statin (n (%)) 81 (66.9)
On fibrate (n (%)) 7 (5.8)
On allopurinol (n (%)) 5 (4.1)
Body mass index (kg/m2)† 31.22 (27.94–34.53)
Body surface area (m2)∗ 1.89± 0.21
Waist index∗ 1.19± 0.14
Pulse rate (bpm)† 68 (61.5–78.5)
Mean systolic pressure (mmHg)∗ 144.19± 17.82
Mean diastolic pressure (mmHg)∗ 84.60± 8.76
Pulse pressure (mmHg)∗ 61.53± 13.66
Mean arterial pressure (mmHg)† 107 (93–113)
White cell count (×109/L)† 7.16 (6.26–8.69)
Haemoglobin (g/dL)† 14.35 (13.33–15.18)
Platelet count (×109/L)† 240.5 (206–284.75)
Red blood cell distribution
width (%)†
13.1 (12.53–13.7)
Mean platelet volume (fL)† 10.9 (10.2–11.6)
Estimated glomerular filtration
rate (mL/min/1.73m2)∗ 91.22± 24.61
Total cholesterol (mmol/L)† 4.12 (3.55–5.15)
HDL cholesterol (mmol/L)† 1.24 (1.06–1.51)
LDL cholesterol (mmol/L)† 2.19 (1.67–3.19)
Table 1: Continued.
Patient characteristics (n = 121) Values
Non-HDL cholesterol (mmol/L)† 2.8 (2.26–3.82)
Triglycerides (mmol/L)† 1.36 (0.97–1.7)
Alkaline phosphatase (mmol/L)† 69 (55–83.5)
Alanine transaminase (mmol/L)† 23 (18–32.5)
Uric acid (μmol/L)∗ 313.05± 79.98
Erythrocyte sedimentation rate
(mm 1st hr)†
10.5 (6–18)
Albumin-creatinine ratio
(mg/mmol)†
7.08 (1–23.34)
Fasting plasma glucose (mmol/L)† 7.08 (6.11–8.18)
Fructosamine (μmol/L)† 278 (257–303)
Glycated haemoglobin (%)† 6.8 (6.3–7.6)
Values are expressed as number (%) of patients, ∗mean ± SD, or †median
(IQR).
Table 2: Baseline continuous glucose-monitoring findings of study
population.
Patient characteristics (n = 121) Values
Highest value (mmol/L) 13.2 (11.3–15.5)
Lowest value (mmol/L) 3.95 (2.93–5.1)
Mean blood glucose (mmol/L) 7.35 (6.63–8.65)
Standard deviation (mmol/L) 1.9 (1.5–2.3)
Number of high excursions 8 (5–10)
Number of low excursions 0 (0–2)
AUC above 7.8mmol/L 0.63 (0.23–1.43)
AUC below 3.9mmol/L 0 (0–0.02)
Duration during 72 hr period
with BG above 7.8mmol/L (%)
37 (19.25–60.75)
Duration during 72 hr period
with BG within 3.9–7.8mmol/L (%)
60 (37.5–77)
Duration during 72 hr period
with BG below 3.9mmol/L (%)
0 (0–4)
Values are expressed as median (IQR). AUC: area under curve.
4 Journal of Diabetes Research
These findings are consistent with those of the Diabetes
Control and Complications Trial (DCCT), which reported
that the rate of severe hypoglycaemic episodes in subjects
with type 1 diabetes was associated with increased coro-
nary calcium score in those with a HbA1c below 7.5%
(58mmol/L) [18]. It is, however, possible that severe hypo-
glycaemia was acting as a marker for increased glucose
fluctuations. Since we performed CGM, we can exclude
this possibility in our study. Furthermore, whilst the DCCT
data showed an association of severe hypoglycaemia with
increased coronary calcium score in type 1 diabetes, the
present study shows a relationship of mild asymptomatic
hypoglycaemia, as detected by CGM, to atherosclerosis in
type 2 diabetes.
We did not find significant associations of any of the
hyperglycaemic indexes (including HbA1c, fructosamine,
AUC> 7.8mmol/L, and duration> 7.8mmol/L) or of glucose
fluctuations (as assessed by standard deviation of blood glu-
cose during CGM) with macrovascular disease. However,
duration of blood glucose> 7.8mmol/L was independently
associated with ACR. These observations may be related to
the short median duration of diabetes in our patients. Our
findings are consistent with clinical trial data which have
shown that lowering blood glucose for a few years is effective
in reducing microvascular but not macrovascular disease
[2, 3]. In the UKPDS, it took 10 years of intensive control
and a further 10 years of follow-up to demonstrate a
beneficial effect of lowering blood glucose on macrovascu-
lar outcomes [20]. Another reason could be the relatively
good glycaemic control in our cohort.
Our data suggest that hypoglycaemia may have a more
rapid effect in promoting atherosclerosis than mild hypergly-
caemia or glucose fluctuations. They may help explain the
relationship between hypoglycaemia and adverse cardio-
vascular outcomes even in the short term and why these
deleterious effects extend well beyond the period of hypo-
glycaemia itself. They may also explain why too aggressive
lowering of blood glucose in the Action to Control Car-
diovascular Risk in Diabetes (ACCORD) trial was associ-
ated with increased mortality [21] and why agents such
Table 3: Demographic and clinical findings of subjects with and without macrovascular disease.
Variable No macrovascular disease (n = 49) Macrovascular disease (n = 72) p value
Age (years)† 66 (62–69) 61 (54.25–67) 0.001
Male : female (n (%)) 34 (69.4) : 15 (30.6) 55 (76.4) : 17 (23.6) 0.41
Diabetes duration (years)† 3.5 (2–5) 3 (2–4) 0.23
Smoking (current/ex/nonsmokers) (n (%)) 4 (8.1)/19 (38.8)/26 (53.1) 18 (25.0)/22 (30.6)/32 (44.4) 0.06
Hypertension (n (%)) 29 (59.18) 51 (70.83) 0.24
Hyperlipidaemia (n (%)) 36 (73.47) 51 (70.83) 0.84
CKD (n (%)) 2 (4.08) 7 (9.72) 0.31
Metformin (n (%)) 44 (89.80) 65 (90.28) 1.00
Sulphonylurea (n (%)) 14 (28.57) 50 (69.44) 0.84
Gliptins (n (%)) 4 (8.16) 2 (2.77) 0.22
Insulin (n (%)) 1 (2.04) 5 (6.94) 0.40
ACEI/ARB (n (%)) 29 (59.18) 48 (66.67) 0.44
β-blocker (n (%)) 7 (14.29) 15 (20.83) 0.47
CCB (n (%)) 11 (22.45) 12 (16.67) 0.48
Diuretic (n (%)) 14 (28.57) 19 (26.39) 0.84
Aspirin (n (%)) 9 (18.36) 29 (40.28) 0.02
Statin (n (%)) 29 (59.18) 52 (72.22) 0.17
Fibrate (n (%)) 6 (12.24) 1 (1.39) 0.02
Allopurinol (n (%)) 2 (4.08) 3 (4.17) 1.00
BMI (kg/m2)† 31.22 (27.67–33.97) 31.31 (27.9–35.19) 0.35
BSA (m2)∗ 1.83± 0.20 1.93± 0.21 0.007
Waist index∗ 1.17± 0.15 1.20± 0.13 0.22
Pulse rate (bpm)† 65 (61–80.25) 71 (62–78) 0.84
Mean SBP (mmHg)∗ 146± 18.28 142.96± 17.54 0.36
Mean DBP (mmHg)∗ 85.66± 7.34 83.88± 9.58 0.25
Pulse pressure (mmHg)∗ 62.18± 15.6 61.07± 12.22 0.68
MAP (mmHg)† 106 (97.5–112.5) 90.75 (107.5–113) 0.77
Values are expressed as number (%) of patients, ∗mean ± SD, or †median (IQR). ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor
blocker; BMI: body mass index; BSA: body surface area; CCB: calcium channel blocker; CKD: chronic kidney disease; CVD: cardiovascular disease; DM:
diabetes mellitus; DBP: diastolic blood pressure; MAP: mean arterial pressure; SBP: systolic blood pressure.
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as sulphonylureas [22, 23]and insulin [24] which are
prone to cause hypoglycaemia have also been associated
with increased mortality and cardiovascular events by
some authors.
Hypoglycaemia can promote atherogenesis in a number
of ways. Acute hypoglycaemia has been shown to result in
decreased nitric oxide bioavailability, increased oxidative
stress [25], platelet activation [26], and release of proinflam-
matory [27], proatherogenic, and prothrombotic cytokines
such as PAI-1, VEGF, vascular adhesion molecules, and
interleukin-6 [26, 28]. Many of these effects may extend to
beyond the hypoglycaemic period [26]. Furthermore, Fadini
and colleagues have recently reported that hypoglycaemia
may impair endothelial progenitor cell response [29]. Inter-
estingly, Peña and colleagues have reported that hypoglycae-
mia, but not glucose variability, is associated with endothelial
dysfunction in children with type 1 diabetes [30].
Body surface area was also found to be independently
associated with atherosclerotic markers. This is probably
related to insulin resistance and/or hyperinsulinaemia.
Table 4: Laboratory findings of subjects with and without macrovascular disease.
Variable No macrovascular disease (n = 49) Macrovascular disease (n = 72) p value
White cell count (×109/L)† 7.09 (5.88–7.87) 7.29 (6.42–9.24) 0.13
Haemoglobin (g/dL)† 14.2 (13.3–15.1) 14.4 (13.6–15.2) 0.48
Platelet count (×109/L)† 242 (204.5–283.5) 239 (206–287) 0.78
RDW (%)† 13 (12.5–13.45) 13.1 (12.6–13.8) 0.13
MPV (fL)† 10.95 (10.23–11.5) 10.9 (10.1–11.6) 0.53
eGFR (mL/min/1.72m2)∗ 87.76± 22.21 93.58± 26.0 0.19
Total cholesterol (mmol/L)† 4.14 (3.65–5.25) 4.1 (3.53–5.11) 0.80
HDL cholesterol (mmol/L)† 1.32 (1.1–1.58) 1.24 (1.04–1.46) 0.07
LDL cholesterol (mmol/L)† 2.3 (1.65–3.36) 2.18 (1.7–3.13) 0.81
Non-HDL cholesterol (mmol/L)† 2.74 (2.18–3.86) 2.83 (2.29–3.78) 0.67
Triglycerides (mmol/L)† 1.13 (0.91–1.64) 1.47 (1.14–1.85) 0.03
ALP (mmol/L)† 66 (52–93) 69 (59.25–80) 0.89
ALT (mmol/L)† 22 (17.5–32) 24 (18–32.75) 0.6
Uric acid (μmol/L)∗ 319.56± 83.19 308.65± 78.03 0.47
ESR (mm 1st hr)† 13 (7–23) 9 (5–17) 0.08
FPG (mmol/L)† 7.14 (6.02–8.53) 7.08 (6.23–8.05) 0.55
Fructosamine (μmol/L)† 281 (259.25–305) 277 (256–303.5) 0.77
HbA1c (%)
† 7.0 (6.3–8.1) 6.7 (6.3–7.4) 0.23
HbA1c (mmol/L)
† 53 (45–65) 50 (45–57) 0.23
Values are expressed as ∗mean ± SD or †median (IQR). Abbreviations: ALP: alkaline phosphatase; ALT: alanine transaminase; eGFR: estimated glomerular
filtration rate; ESR: erythrocyte sedimentation rate; FPG: fasting plasma glucose; HbA1c: glycated haemoglobin; MPV: mean platelet volume; RDW: red
blood cell distribution width.
Table 5: Continuous glucose-monitoring findings of subjects with and without macrovascular disease.
Variable
No macrovascular disease
(n = 49)
Macrovascular disease
(n = 72) p value
Highest value (mmol/L)† 13.4 (11.3–15.85) 13.0 (11.3–15) 0.35
Lowest value (mmol/L)† 4.4 (3.2–5.25) 3.7 (2.8–5) 0.09
Mean blood glucose (mmol/L)† 7.6 (6.85–9.0) 7.3 (6.6–8.4) 0.3
Standard deviation (mmol/L)† 3.0 (1.3–2.3) 1.8 (1.5–2.4) 0.9
Number of high excursions† 8 (6–10) 8 (5–10) 0.49
Number of low excursions† 0 (0–2) 1 (0–2) 0.10
AUC above 7.8mmol/L† 0.64 (0.24–1.76) 0.57 (0.21–1.35) 0.39
AUC below 3.9mmol/L† 0 (0–0.01) 0 (0–0.03) 0.05
Duration during 72 hr period with BG above 7.8mmol/L (%)† 37 (18.5–66.5) 35 (20–58) 0.39
Duration during 72 hr period with BG within 3.9–7.8mmol/L (%)† 58 (31.5–79) 60 (41–77) 0.63
Duration during 72 hr period with BG below 3.9mmol/L (%)† 0 (0-1) 1 (0–5) 0.02
Values are expressed as number (%) of patients or †median (IQR). AUC: area under curve.
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The patients with macrovascular disease were on average
younger than those without macrovascular disease. This
could be due to the cross-sectional nature of our study.
Macrovascular disease shortens life expectancy resulting in
a lower average age of subjects with macrovascular disease
compared to subjects without. Furthermore, macrovascular
disease was associated with hypoglycaemia, which is also
known to decrease survival [21]. Duration of diabetes was
similar in both groups, meaning that those with macrovascu-
lar disease had younger onset type 2 diabetes, which might be
associated with higher mortality [31].
A limitation of our study is that we have no information
on antecedent glycaemic indexes. This problem is inherent to
the study area as it is not practical or ethical to perform CGM
over a number of years and not alter management in order to
keep glycaemic parameters stable. However, we tried to
reduce the impact of this limitation in a number of ways.
Firstly, we only recruited patients with stable control,
namely, not needing escalation of treatment. Secondly, we
studied patients with short duration of diabetes because such
patients are less likely to have variation in their glycaemic
parameters over the course of their disease. Thirdly, we per-
formed blind, rather than real-time, CGM so that patients
did not alter their behaviour as result of the glucose readings.
Additionally, patients were instructed not to change their
usual routines. In this way, the CGM data are more likely
to be representative of the patients’ usual glycaemic profile.
Furthermore, many glycaemic indices such as HbA1c [32]
and hypoglycaemia [11] have been shown to exhibit signifi-
cant temporal tracking. Another limitation is that in view
of the cross-sectional nature of our study, we cannot prove
causal relationships. It is possible that those with macrovas-
cular disease were treated more aggressively, hence causing
more hypoglycaemia. However, this would not explain the
observed relationship with CIMT, which is a subclinical
marker of atherosclerosis.
In conclusion, the study suggests that mild asymptomatic
hypoglycaemia in subjects with type 2 diabetes is associated
with atherosclerotic disease. This cannot be explained by an
association of hypoglycaemia with hyperglycaemia or glucose
fluctuations. Hyperglycaemic load, as measured by AUC for
BG> 7.8mmol/L, was associated with microalbuminuria.
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